依达拉奉右莰醇对发病48h内中度脑梗死患者的治疗效果

Therapeutic Effect of Edaravone Dexborneol in Patients with Moderate Cerebral Infarction Onset within 48 Hours

目的:研究发病48 h内中度脑梗死患者采用依达拉奉右莰醇治疗的效果。方法:选取2021年9月—2022年9月江苏省邳州市人民医院收治的中度脑梗死患者76例作为研究对象,随机分为观察组与对照组,各38例。对照组给予依达拉奉治疗,观察组给予依达拉奉右莰醇治疗。比较两组神经功能缺损情况,生活能力,活动能力,血清诱导型一氧化氮合成酶(iNOS)、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)水平及临床疗效。结果:治疗后,两组美国国立卫生院卒中量表、改良Rankin量表评分低于治疗前,且观察组低于对照组,两组改良Barthel指数高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组iNOS、TNF-α和IL-1β水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.001)。观察组治疗总有效率高于对照组,差异有统计学意义(P<0.001)。结论:依达拉奉右莰醇注射液治疗发病48 h内中度脑梗死的效果显著,可改善患者神经功能、生活能力、活动能力,提高临床疗效,值得临床推广。

Objective:To study the effect of edaravone dexborneol treatment in patients with moderate cerebral infarction onset within 48 h.Methods:A total of 76 patients with moderate cerebral infarction in Pizhou People′s Hospital from September 2021 to September 2022 were selected as the study subjects.They were randomly divided into the observation group and the control group,with 38 cases in each group.The control group was treated with edaravone and the observation group was treated with edaravone dexborneol.The neurological deficits,living ability,movement ability,serum inducible nitric oxide synthase(iNOS),tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β)levels and clinical efficacy were compared between the two groups.Results:After treatment,the scores of the National Institute of Health stroke scale and modified Rankin scale in the two groups were lower than those before treatment,and the observation group was lower than the control group;the modified Barthel index in the two groups was higher than that before treatment,and the observation group was higher than the control group;the difference was statistically significant(P<0.05).After treatment,the levels of iNOS,TNF-αand IL-1βin two groups were lower than those before treatment,and the observation group was lower than the control group,and the difference was statistically significant(P<0.001).The overall response rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.001).Conclusion:Edaravone dexborneol injection has a significant effect in the treatment of moderate cerebral infarction onset within 48 h,which can improve patients′neurological function,living ability,movement ability,and improve clinical efficacy,which is worthy of clinical promotion.